-
1
-
-
0036468440
-
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a phase II study
-
Ajani, J.A., Baker, J., Pisters, P.W., Ho, L., Mansfield, P.F., Feig, B.W. et al. (2002) CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a phase II study. Cancer 94: 641-646.
-
(2002)
Cancer
, vol.94
, pp. 641-646
-
-
Ajani, J.A.1
Baker, J.2
Pisters, P.W.3
Ho, L.4
Mansfield, P.F.5
Feig, B.W.6
-
2
-
-
53749102232
-
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: Rtog 0113
-
Ajani, J.A., Winter, K., Komaki, R., Kelsen, D.P., Minsky, B.D., Liao, Z. et al. (2008) Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: Rtog 0113. J Clin Oncol 26: 4551-4556.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4551-4556
-
-
Ajani, J.A.1
Winter, K.2
Komaki, R.3
Kelsen, D.P.4
Minsky, B.D.5
Liao, Z.6
-
3
-
-
84993825501
-
Long term results of the MRC OEO 2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer
-
Gastrointestinal Cancer Symposium Orlando, FL: USA, 25-25 January Abstract 9
-
Allum, W.H., Fogarty, P.J., Stenning, S.P., Langley, R.E. and Group, N.U.G.C.C.S. ( 2008) Long term results of the MRC OEO 2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 25-25 January 2008: Abstract 9.
-
(2008)
-
-
Allum, W.H.1
Fogarty, P.J.2
Stenning, S.P.3
Langley, R.E.4
Group, N.U.G.C.C.S.5
-
4
-
-
33750719996
-
MET receptor signaling: A key effector in esophageal adenocarcinoma
-
Anderson, M.R., Harrison, R., Atherfold, P.A., Campbell, M.J., Darnton, S.J., Obszynska, J. et al. (2006) MET receptor signaling: A key effector in esophageal adenocarcinoma. Clin Cancer Res 12: 5936-5943.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5936-5943
-
-
Anderson, M.R.1
Harrison, R.2
Atherfold, P.A.3
Campbell, M.J.4
Darnton, S.J.5
Obszynska, J.6
-
5
-
-
70450209516
-
Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the Toga trial
-
Amercan Society of Clinical Oncology, Annual Proceedings Orlando, FL: USA, 29 May-2 June Abstract: 4556
-
Bang, Y., Chung, H., Xu, J., Lordick, F., Sawaki, A., Lipatov, O. et al. (2009) Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the Toga trial. Amercan Society of Clinical Oncology, Annual Proceedings, Orlando, FL, USA, 29 May-2 June 2009. Abstract: 4556.
-
(2009)
-
-
Bang, Y.1
Chung, H.2
Xu, J.3
Lordick, F.4
Sawaki, A.5
Lipatov, O.6
-
6
-
-
34247150339
-
Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102
-
Bedenne, L., Michel, P., Bouche, O., Milan, C., Mariette, C., Conroy, T. et al. (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25: 1160-1168.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1160-1168
-
-
Bedenne, L.1
Michel, P.2
Bouche, O.3
Milan, C.4
Mariette, C.5
Conroy, T.6
-
7
-
-
22344446070
-
Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival
-
Berger, A.C., Farma, J., Scott, W.J., Freedman, G., Weiner, L., Cheng, J.D. et al. (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23: 4330-4337.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4330-4337
-
-
Berger, A.C.1
Farma, J.2
Scott, W.J.3
Freedman, G.4
Weiner, L.5
Cheng, J.D.6
-
8
-
-
67549105888
-
(2009) Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial
-
Phila Pa
-
Bertagnolli, M.M., Eagle, C.J., Zauber, A.G., Redston, M., Breazna, A., Kim, K. et al. (2009) Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res ( Phila Pa) 2: 310-321.
-
Cancer Prev Res
, vol.2
, pp. 310-321
-
-
Bertagnolli, M.M.1
Eagle, C.J.2
Zauber, A.G.3
Redston, M.4
Breazna, A.5
Kim, K.6
-
9
-
-
35848968863
-
-
Abstract
-
Boige, V., Pignon, J., Saint-Aubert, B., Lasser, P., Conroy, T., Bouché, O. et al. (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC Accord 07-FFCD 9703 trial. American Society of Clinical Oncology, Chicago, I.L., USA, 1-5 June 2007. Abstract: 4510.
-
(2007)
Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC Accord 07-FFCD 9703 trial. American Society of Clinical Oncology, Chicago, I.L., USA, 1-5 June 2007
, pp. 4510
-
-
Boige, V.1
Pignon, J.2
Saint-Aubert, B.3
Lasser, P.4
Conroy, T.5
Bouché, O.6
-
10
-
-
32144433159
-
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
-
Bonner, J.A., Harari, P.M., Giralt, J., Azarnia, N., Shin, D.M., Cohen, R.B. et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578.
-
(2006)
N Engl J Med
, vol.354
, pp. 567-578
-
-
Bonner, J.A.1
Harari, P.M.2
Giralt, J.3
Azarnia, N.4
Shin, D.M.5
Cohen, R.B.6
-
11
-
-
49149112670
-
mTOR in squamous cell carcinoma of the oesophagus: A potential target for molecular therapy?
-
Boone, J., Ten Kate, F.J., Offerhaus, G.J., van Diest, P.J., Rinkes, I.H. and van Hillegersberg, R. ( 2008) mTOR in squamous cell carcinoma of the oesophagus: A potential target for molecular therapy? J Clin Pathol 61: 909-913.
-
(2008)
J Clin Pathol
, vol.61
, pp. 909-913
-
-
Boone, J.1
Ten Kate, F.J.2
Offerhaus, G.J.3
van Diest, P.J.4
Rinkes, I.H.5
van Hillegersberg, R.6
-
12
-
-
61549099373
-
Molecular biological challenges in the treatment of esophageal adenocarcinoma
-
Boonstra, J.J., Dinjens, W.N., Tilanus, H.W. and Koppert, L.B. ( 2007) Molecular biological challenges in the treatment of esophageal adenocarcinoma. Expert Rev Gastroenterol Hepatol 1: 275-286.
-
(2007)
Expert Rev Gastroenterol Hepatol
, vol.1
, pp. 275-286
-
-
Boonstra, J.J.1
Dinjens, W.N.2
Tilanus, H.W.3
Koppert, L.B.4
-
13
-
-
0030793423
-
Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus
-
Bosset, J.F., Gignoux, M., Triboulet, J.P., Tiret, E., Mantion, G., Elias, D. et al. (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337: 161-167.
-
(1997)
N Engl J Med
, vol.337
, pp. 161-167
-
-
Bosset, J.F.1
Gignoux, M.2
Triboulet, J.P.3
Tiret, E.4
Mantion, G.5
Elias, D.6
-
14
-
-
4043057156
-
Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy
-
Brenner, B., Ilson, D.H., Minsky, B.D., Bains, M.S., Tong, W., Gonen, M. et al. (2004) Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 22: 45-52.
-
(2004)
J Clin Oncol
, vol.22
, pp. 45-52
-
-
Brenner, B.1
Ilson, D.H.2
Minsky, B.D.3
Bains, M.S.4
Tong, W.5
Gonen, M.6
-
15
-
-
0033963379
-
HER-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma
-
Brien, T.P., Odze, R.D., Sheehan, C.E., Mckenna, B.J. and Ross, J.S. ( 2000) HER-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. Hum Pathol 31: 35-39.
-
(2000)
Hum Pathol
, vol.31
, pp. 35-39
-
-
Brien, T.P.1
Odze, R.D.2
Sheehan, C.E.3
Mckenna, B.J.4
Ross, J.S.5
-
16
-
-
24044509153
-
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial
-
Burmeister, B.H., Smithers, B.M., Gebski, V., Fitzgerald, L., Simes, R.J., Devitt, P. et al. (2005) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol 6: 659-668.
-
(2005)
Lancet Oncol
, vol.6
, pp. 659-668
-
-
Burmeister, B.H.1
Smithers, B.M.2
Gebski, V.3
Fitzgerald, L.4
Simes, R.J.5
Devitt, P.6
-
17
-
-
24644445676
-
Increased HER 2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients
-
Cappuzzo, F., Varella-Garcia, M., Shigematsu, H., Domenichini, I., Bartolini, S., Ceresoli, G.L. et al. (2005) Increased HER 2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23: 5007-5018.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5007-5018
-
-
Cappuzzo, F.1
Varella-Garcia, M.2
Shigematsu, H.3
Domenichini, I.4
Bartolini, S.5
Ceresoli, G.L.6
-
18
-
-
0033526355
-
Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group
-
Cooper, J.S., Guo, M.D., Herskovic, A., Macdonald, J.S., Martenson Jr, J.A., Al-Sarraf, M. et al. (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281: 1623-1627.
-
(1999)
JAMA
, vol.281
, pp. 1623-1627
-
-
Cooper, J.S.1
Guo, M.D.2
Herskovic, A.3
Macdonald, J.S.4
Martenson Jr, J.A.5
Al-Sarraf, M.6
-
19
-
-
0037219463
-
Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis
-
Corley, D.A., Kerlikowske, K., Verma, R. and Buffler, P. ( 2003) Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology 124: 47-56.
-
(2003)
Gastroenterology
, vol.124
, pp. 47-56
-
-
Corley, D.A.1
Kerlikowske, K.2
Verma, R.3
Buffler, P.4
-
20
-
-
33745726677
-
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
-
Cunningham, D., Allum, W.H., Stenning, S.P., Thompson, J.N., van de Velde, C.J., Nicolson, M. et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20.
-
(2006)
N Engl J Med
, vol.355
, pp. 11-20
-
-
Cunningham, D.1
Allum, W.H.2
Stenning, S.P.3
Thompson, J.N.4
van de Velde, C.J.5
Nicolson, M.6
-
21
-
-
13744254574
-
Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention
-
Dannenberg, A.J., Lippman, S.M., Mann, J.R., Subbaramaiah, K. and Dubois, R.N. ( 2005) Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol 23: 254-266.
-
(2005)
J Clin Oncol
, vol.23
, pp. 254-266
-
-
Dannenberg, A.J.1
Lippman, S.M.2
Mann, J.R.3
Subbaramaiah, K.4
Dubois, R.N.5
-
22
-
-
33845863415
-
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer
-
Dawson, S.J., Michael, M., Biagi, J., Foo, K.F., Jefford, M., Ngan, S.Y. et al. (2007) A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs 25: 123-129.
-
(2007)
Invest New Drugs
, vol.25
, pp. 123-129
-
-
Dawson, S.J.1
Michael, M.2
Biagi, J.3
Foo, K.F.4
Jefford, M.5
Ngan, S.Y.6
-
23
-
-
74049108229
-
(2009) Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer
-
Debucquoy, A., Haustermans, K., Daemen, A., Aydin, S., Libbrecht, L., Gevaert, O. et al. (2009) Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 27: 2751-2757.
-
J Clin Oncol
, vol.27
, pp. 2751-2757
-
-
Debucquoy, A.1
Haustermans, K.2
Daemen, A.3
Aydin, S.4
Libbrecht, L.5
Gevaert, O.6
-
24
-
-
33646089413
-
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: A phase I study
-
Dobelbower, M.C., Russo, S.M., Raisch, K.P., Seay, L.L., Clemons, L.K., Suter, S. et al. (2006) Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: A phase I study. Anticancer Drugs 17: 95-102.
-
(2006)
Anticancer Drugs
, vol.17
, pp. 95-102
-
-
Dobelbower, M.C.1
Russo, S.M.2
Raisch, K.P.3
Seay, L.L.4
Clemons, L.K.5
Suter, S.6
-
25
-
-
33750618860
-
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
-
Dragovich, T., McCoy, S., Fenoglio-Preiser, C.M., Wang, J., Benedetti, J.K., Baker, A.F. et al. (2006) Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 24: 4922-4927.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4922-4927
-
-
Dragovich, T.1
McCoy, S.2
Fenoglio-Preiser, C.M.3
Wang, J.4
Benedetti, J.K.5
Baker, A.F.6
-
26
-
-
0029028564
-
The significance of C-ERB B-2 and P 53 immunoreactivity in patients with adenocarcinoma of the esophagus
-
Duhaylongsod, F.G., Gottfried, M.R., Iglehart, J.D., Vaughn, A.L. and Wolfe, W.G. ( 1995) The significance of C-ERB B-2 and P 53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 221: 677-683.
-
(1995)
Ann Surg
, vol.221
, pp. 677-683
-
-
Duhaylongsod, F.G.1
Gottfried, M.R.2
Iglehart, J.D.3
Vaughn, A.L.4
Wolfe, W.G.5
-
27
-
-
34248661810
-
Phase II study of bevacizumab anddocetaxel (avatax) in metastatic esophageal and gastric cancer
-
Enzinger, P.C., Fidias, P., Stuart, K. and Al, E. ( 2006) Phase II study of bevacizumab anddocetaxel (avatax) in metastatic esophageal and gastric cancer. Ann Oncol 17: 1078PDa.
-
(2006)
Ann Oncol
, vol.17
, pp. 1078PDa
-
-
Enzinger, P.C.1
Fidias, P.2
Stuart, K.3
Al, E.4
-
28
-
-
34247126732
-
-
American Society of Clinical Oncology Chicago, IL: USA Abstract
-
Enzinger, P.C., Mamon, H., Choi, N., Bueno, R., Kulke, M.H., Fidias, P. et al. (2004) Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. American Society of Clinical Oncology, Chicago, IL, USA, 2004: Abstract 35.
-
(2004)
Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer
, pp. 35
-
-
Enzinger, P.C.1
Mamon, H.2
Choi, N.3
Bueno, R.4
Kulke, M.H.5
Fidias, P.6
-
29
-
-
84993792112
-
-
American Society of Clinial Oncology Chicago, IL: USA: Abstract
-
Enzinger, P.C., Ryan, D.P., Regan, E.M., Lehman, N., Abrams, T.A., Hezel, A.F. et al. (2008) Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. American Society of Clinial Oncology, Chicago, IL, USA: Abstract 4552.
-
(2008)
Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer
, pp. 4552
-
-
Enzinger, P.C.1
Ryan, D.P.2
Regan, E.M.3
Lehman, N.4
Abrams, T.A.5
Hezel, A.F.6
-
30
-
-
78651423248
-
-
American Society of Clinical Oncology Orlando, FL: USA, 1-5 June 2006: Abstract
-
Enzinger, P.C., Yock, T., Suh, W., Fidias, P., Mamon, H., Choi, N. et al. (2006) Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. American Society of Clinical Oncology, Orlando, FL, USA, 1-5 June 2006: Abstract 4064.
-
(2006)
Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer
, pp. 4064
-
-
Enzinger, P.C.1
Yock, T.2
Suh, W.3
Fidias, P.4
Mamon, H.5
Choi, N.6
-
31
-
-
58249090429
-
(2009) Biomarkers of response to therapy in oesophago-gastric cancer
-
Fareed, K.R., Kaye, P., Soomro, I.N., Ilyas, M., Martin, S., Parsons, S.L. et al. (2009) Biomarkers of response to therapy in oesophago-gastric cancer. Gut 58: 127-143.
-
Gut
, vol.58
, pp. 127-143
-
-
Fareed, K.R.1
Kaye, P.2
Soomro, I.N.3
Ilyas, M.4
Martin, S.5
Parsons, S.L.6
-
32
-
-
3042584502
-
Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis
-
Fiorica, F., Di Bona, D., Schepis, F., Licata, A., Shahied, L., Venturi, A. et al. (2004) Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut 53: 925-930.
-
(2004)
Gut
, vol.53
, pp. 925-930
-
-
Fiorica, F.1
Di Bona, D.2
Schepis, F.3
Licata, A.4
Shahied, L.5
Venturi, A.6
-
33
-
-
33847156303
-
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis
-
Gebski, V., Burmeister, B., Smithers, B.M., Foo, K., Zalcberg, J. and Simes, J. ( 2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 8: 226-234.
-
(2007)
Lancet Oncol
, vol.8
, pp. 226-234
-
-
Gebski, V.1
Burmeister, B.2
Smithers, B.M.3
Foo, K.4
Zalcberg, J.5
Simes, J.6
-
34
-
-
84993723639
-
-
Amercan Society of Clinical Oncology Chigago IL, USA: Abstract
-
Gold, P.J., Goldman, B., Iqbal, S., Leichman, L.P., Lenz, H.J. and Blanke, C.D. ( 2008) Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group Study. Amercan Society of Clinical Oncology, Chigago, IL, USA: Abstract 4536.
-
(2008)
Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group Study
, pp. 4536
-
-
Gold, P.J.1
Goldman, B.2
Iqbal, S.3
Leichman, L.P.4
Lenz, H.J.5
Blanke, C.D.6
-
35
-
-
17944362255
-
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: Preliminary results
-
Williston Park
-
Govindan, R., Mcleod, H., Mantravadi, P., Fineberg, N., Helft, P., Kesler, K. et al. (2004) Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: Preliminary results. Oncology (Williston Park) 18: 18-21.
-
(2004)
Oncology
, vol.18
, pp. 18-21
-
-
Govindan, R.1
Mcleod, H.2
Mantravadi, P.3
Fineberg, N.4
Helft, P.5
Kesler, K.6
-
36
-
-
0037129734
-
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial
-
Group, M.R.C.O.C.W. ( 2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 359: 1727-1733.
-
(2002)
Lancet
, vol.359
, pp. 1727-1733
-
-
Group, M.R.C.O.C.W.1
-
37
-
-
33646706077
-
Gefitinib-sensitizing mutations in esophageal carcinoma
-
Guo, M., Liu, S. and Lu, F. ( 2006) Gefitinib-sensitizing mutations in esophageal carcinoma. N Engl J Med 354: 2193-2194.
-
(2006)
N Engl J Med
, vol.354
, pp. 2193-2194
-
-
Guo, M.1
Liu, S.2
Lu, F.3
-
38
-
-
0026326516
-
Theory and application of early systemic therapy
-
Harris, D.T. and Mastrangelo, M.J. ( 1991) Theory and application of early systemic therapy. Semin Oncol 18: 493-503.
-
(1991)
Semin Oncol
, vol.18
, pp. 493-503
-
-
Harris, D.T.1
Mastrangelo, M.J.2
-
39
-
-
33646594999
-
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (MMP) inhibitor prinomastat in patients with esophageal adenocarcinoma
-
Heath, E.I., Burtness, B.A., Kleinberg, L., Salem, R.R., Yang, S.C., Heitmiller, R.F. et al. (2006) Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (MMP) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs 24: 135-140.
-
(2006)
Invest New Drugs
, vol.24
, pp. 135-140
-
-
Heath, E.I.1
Burtness, B.A.2
Kleinberg, L.3
Salem, R.R.4
Yang, S.C.5
Heitmiller, R.F.6
-
40
-
-
84859413249
-
Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: Phase II efficacy and biomarker analyses
-
Gastrointestinal Cancer Symposium Orlando, FL: USA, 15-17 January Abstract 43
-
Hecht, J.R., Urba, S.G., Koehler, M., Ellis, C., Gagnon, R., Kemner, A. et al. (2008) Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: Phase II efficacy and biomarker analyses. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 15-17 January 2008: Abstract 43.
-
(2008)
-
-
Hecht, J.R.1
Urba, S.G.2
Koehler, M.3
Ellis, C.4
Gagnon, R.5
Kemner, A.6
-
41
-
-
0026769381
-
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus
-
Herskovic, A., Martz, K., Al-Sarraf, M., Leichman, L., Brindle, J., Vaitkevicius, V. et al. (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593-1598.
-
(1992)
N Engl J Med
, vol.326
, pp. 1593-1598
-
-
Herskovic, A.1
Martz, K.2
Al-Sarraf, M.3
Leichman, L.4
Brindle, J.5
Vaitkevicius, V.6
-
42
-
-
60849109531
-
(2009) Genetic variations in the PI3k/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy
-
Hildebrandt, M.A., Yang, H., Hung, M.C., Izzo, J.G., Huang, M., Lin, J. et al. (2009) Genetic variations in the PI3k/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27: 857-871.
-
J Clin Oncol
, vol.27
, pp. 857-871
-
-
Hildebrandt, M.A.1
Yang, H.2
Hung, M.C.3
Izzo, J.G.4
Huang, M.5
Lin, J.6
-
43
-
-
84993746651
-
Adjuvant sunitinib following chemoradiotherapy and surgery for esophageal cancer: A phase II trial
-
Gastrointestinal Cancer Symposium Orlando, FL: USA, 15-17 January Abstract 109
-
Horgan, A.M., Darling, G., Wong, R., Liu, G., Jonker, D., Hornby, J. et al. (2009) Adjuvant sunitinib following chemoradiotherapy and surgery for esophageal cancer: A phase II trial. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 15-17 January 2009: Abstract 109.
-
(2009)
-
-
Horgan, A.M.1
Darling, G.2
Wong, R.3
Liu, G.4
Jonker, D.5
Hornby, J.6
-
44
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
-
45
-
-
0042887575
-
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer
-
Ilson, D.H., Bains, M., Kelsen, D.P., O’Reilly, E., Karpeh, M., Coit, D. et al. (2003) Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 21: 2926-2932.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2926-2932
-
-
Ilson, D.H.1
Bains, M.2
Kelsen, D.P.3
O’Reilly, E.4
Karpeh, M.5
Coit, D.6
-
46
-
-
78651420594
-
Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (Rt) in esophageal adenocarcinoma: Preliminary safety analysis
-
American Society of Clinial Oncology, Annual Proceedings Orlando, FL: USA: Abstract 4573
-
Ilson, D.H., Bains, M., Rizk, N., Rusch, V., Flores, R., Park, B. et al. (2009 a) Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (Rt) in esophageal adenocarcinoma: Preliminary safety analysis. American Society of Clinial Oncology, Annual Proceedings: Orlando, FL, USA: Abstract 4573.
-
(2009)
-
-
Ilson, D.H.1
Bains, M.2
Rizk, N.3
Rusch, V.4
Flores, R.5
Park, B.6
-
47
-
-
78651420594
-
Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (Rt) in esophageal adenocarcinoma: Preliminary safety analysis
-
Gastrointestinal Cancer Symposium Orlando, FL: USA, 15-17 January Abstract 79
-
Ilson, D.H., Bains, M., Rizk, N., Rusch, V., Flores, R., Park, B. et al. (2009 b) Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (Rt) in esophageal adenocarcinoma: Preliminary safety analysis. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 15-17 January 2009: Abstract 79.
-
(2009)
-
-
Ilson, D.H.1
Bains, M.2
Rizk, N.3
Rusch, V.4
Flores, R.5
Park, B.6
-
48
-
-
0032887574
-
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer
-
Ilson, D.H., Saltz, L., Enzinger, P., Huang, Y., Kornblith, A., Gollub, M. et al. (1999) Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17: 3270-3275.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3270-3275
-
-
Ilson, D.H.1
Saltz, L.2
Enzinger, P.3
Huang, Y.4
Kornblith, A.5
Gollub, M.6
-
49
-
-
79957801244
-
-
American Society of Clinical Oncology Chicago, IL: USA, 1-5 June Abstract
-
Iqbal, S., Goldman, B., Lenz, H.J., Fenoglio-Preiser, C.M. and Blanke, C.D. ( 2007) S0413: A phase II SWOG study of G.W. 572016 (lapatinib) as first line therapy in patients (Pts) with advanced or metastatic gastric cancer. American Society of Clinical Oncology, Chicago, IL, USA, 1-5 June 2007: Abstract 4621.
-
(2007)
S0413: A phase II SWOG study of G.W. 572016 (lapatinib) as first line therapy in patients (Pts) with advanced or metastatic gastric cancer
, pp. 4621
-
-
Iqbal, S.1
Goldman, B.2
Lenz, H.J.3
Fenoglio-Preiser, C.M.4
Blanke, C.D.5
-
50
-
-
66949128313
-
(2009) Biomarkers in gastroenterology: Between hope and hype comes histopathology
-
Jankowski, J.A. and Odze, R.D. (2009) Biomarkers in gastroenterology: Between hope and hype comes histopathology. Am J Gastroenterol 104: 1093-1096.
-
Am J Gastroenterol
, vol.104
, pp. 1093-1096
-
-
Jankowski, J.A.1
Odze, R.D.2
-
51
-
-
41349099104
-
Cancer statistics
-
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
-
(2008)
CA Cancer J Clin
, vol.58
, pp. 71-96
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Hao, Y.4
Xu, J.5
Murray, T.6
-
52
-
-
84993746679
-
Phase II study of modified docetaxel, cisplatin, fluorouracil (MDCF), and bevacizumab (Bev) in patients with metastatic gastroesophageal (Ge) adenocarcinoma
-
Gastrointestinal Cancer Symposium, San Francisco, CA: USA, 15-17 January Abstract 10
-
Jhawer, M., Tse, A., Ilson, D.H., Robinson, E., Zheng, J., Randazzo, J. et al. (2009) Phase II study of modified docetaxel, cisplatin, fluorouracil (MDCF), and bevacizumab (Bev) in patients with metastatic gastroesophageal (Ge) adenocarcinoma. Gastrointestinal Cancer Symposium, San Francisco, CA, USA, 15-17 January 2009: Abstract 10.
-
(2009)
-
-
Jhawer, M.1
Tse, A.2
Ilson, D.H.3
Robinson, E.4
Zheng, J.5
Randazzo, J.6
-
53
-
-
84866865868
-
-
Amercan Society of Clinical Oncology Chigago, IL: USA: Abstract
-
Jhawer, M.P., Kindler, H.L., Wainberg, Z.A., Hecht, J.R., Kerr, R.O., Ford, J.M. et al. (2008) Preliminary activity of Xl 880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study. Amercan Society of Clinical Oncology, Chigago, IL, USA: Abstract 4572.
-
(2008)
Preliminary activity of Xl 880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study
, pp. 4572
-
-
Jhawer, M.P.1
Kindler, H.L.2
Wainberg, Z.A.3
Hecht, J.R.4
Kerr, R.O.5
Ford, J.M.6
-
54
-
-
70449449591
-
-
Amercan Society of Clinical Oncology Chigago, IL: USA: Abstract
-
Jouve, J., Michel, P., Mariette, C., Bonnetain, F., Bouché, O., Conroy, T. et al. (2008) Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus. Amercan Society of Clinical Oncology, Chigago, IL, USA: Abstract 4555.
-
(2008)
Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus
, pp. 4555
-
-
Jouve, J.1
Michel, P.2
Mariette, C.3
Bonnetain, F.4
Bouché, O.5
Conroy, T.6
-
55
-
-
33646568784
-
Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world
-
Kamangar, F., Dores, G.M. and Anderson, W.F. ( 2006) Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2137-2150
-
-
Kamangar, F.1
Dores, G.M.2
Anderson, W.F.3
-
56
-
-
67650395450
-
-
American Society of Clinical Oncology Chicago, IL: USA, 1-5 June Abstract
-
Kang, Y., Bang, Y., Lordick, F., Park, S., Sawaki, A., Chung, H. et al. (2008) Incidence of gastric and gastro-esophageal cancer in the Toga trial: Correlation with HER 2 positivity. American Society of Clinical Oncology, Chicago, IL, USA, 1-5 June 2008: Abstract 11.
-
(2008)
Incidence of gastric and gastro-esophageal cancer in the Toga trial: Correlation with HER 2 positivity
, pp. 11
-
-
Kang, Y.1
Bang, Y.2
Lordick, F.3
Park, S.4
Sawaki, A.5
Chung, H.6
-
57
-
-
34347393724
-
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas
-
Karamouzis, M.V., Grandis, J.R. and Argiris, A. ( 2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Jama 298: 70-82.
-
(2007)
Jama
, vol.298
, pp. 70-82
-
-
Karamouzis, M.V.1
Grandis, J.R.2
Argiris, A.3
-
58
-
-
0036292971
-
Circulating VEGF levels in the serum of gastric cancer patients: Correlation with pathological variables, patient survival, and tumor surgery
-
Karayiannakis, A.J., Syrigos, K.N., Polychronidis, A., Zbar, A., Kouraklis, G., Simopoulos, C. et al. (2002) Circulating VEGF levels in the serum of gastric cancer patients: Correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 236: 37-42.
-
(2002)
Ann Surg
, vol.236
, pp. 37-42
-
-
Karayiannakis, A.J.1
Syrigos, K.N.2
Polychronidis, A.3
Zbar, A.4
Kouraklis, G.5
Simopoulos, C.6
-
59
-
-
33846564399
-
Cetuximab induced antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma
-
Kawaguchi, Y., Kono, K., Mimura, K., Sugai, H., Akaike, H. and Fujii, H. ( 2007) Cetuximab induced antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 120: 781-787.
-
(2007)
Int J Cancer
, vol.120
, pp. 781-787
-
-
Kawaguchi, Y.1
Kono, K.2
Mimura, K.3
Sugai, H.4
Akaike, H.5
Fujii, H.6
-
60
-
-
0032585510
-
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer
-
Kelsen, D.P., Ginsberg, R., Pajak, T.F., Sheahan, D.G., Gunderson, L., Mortimer, J. et al. (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339: 1979-1984.
-
(1998)
N Engl J Med
, vol.339
, pp. 1979-1984
-
-
Kelsen, D.P.1
Ginsberg, R.2
Pajak, T.F.3
Sheahan, D.G.4
Gunderson, L.5
Mortimer, J.6
-
61
-
-
84993692106
-
Analysis of survival with modified docetaxel, cisplatin, fluorouracil (MDCF), and bevacizumab (Bev) in patients with metastatic gastroesophageal (Ge) adenocarcinoma: Results of a phase II clinical trial
-
Amercan Society of Clinical Oncology, Annual Proceedings Orlando, FL: Abstract #4512
-
Kelsen, D.P., Jhawer, M., Ilson, D.H., Tse, A., Randazzo, J., Robinson, E. et al. (2009) Analysis of survival with modified docetaxel, cisplatin, fluorouracil (MDCF), and bevacizumab (Bev) in patients with metastatic gastroesophageal (Ge) adenocarcinoma: Results of a phase II clinical trial. Amercan Society of Clinical Oncology, Annual Proceedings, Orlando, FL: Abstract #4512.
-
(2009)
-
-
Kelsen, D.P.1
Jhawer, M.2
Ilson, D.H.3
Tse, A.4
Randazzo, J.5
Robinson, E.6
-
62
-
-
0037096754
-
Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: Report of a clinical trial for patients with esophageal cancer
-
Khushalani, N.I., Leichman, C.G., Proulx, G., Nava, H., Bodnar, L., Klippenstein, D. et al. (2002) Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: Report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20: 2844-2850.
-
(2002)
J Clin Oncol
, vol.20
, pp. 2844-2850
-
-
Khushalani, N.I.1
Leichman, C.G.2
Proulx, G.3
Nava, H.4
Bodnar, L.5
Klippenstein, D.6
-
63
-
-
3843150503
-
Vascular endothelial growth factor in esophageal cancer
-
Kleespies, A., Guba, M., Jauch, K.W. and Bruns, C.J. ( 2004) Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 87: 95-104.
-
(2004)
J Surg Oncol
, vol.87
, pp. 95-104
-
-
Kleespies, A.1
Guba, M.2
Jauch, K.W.3
Bruns, C.J.4
-
64
-
-
57149085189
-
-
American Society of Clinical Oncology Chicago, IL: USA, 1-5 June Abstract
-
Kleinberg, L., Powell, M.E., Forastiere, A., Keller, S., Anne, P. and Benson, A.B. ( 2007) E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus. American Society of Clinical Oncology, Chicago, IL, USA, 1-5 June 2007 : Abstract 4533.
-
(2007)
E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus
, pp. 4533
-
-
Kleinberg, L.1
Powell, M.E.2
Forastiere, A.3
Keller, S.4
Anne, P.5
Benson, A.B.6
-
65
-
-
84993712568
-
Phase II trial of pre-operative cisplatin/irinotecan and radiotherapy for locally advanced esophageal cancer: Pet scan after induction therapy may identify early treatment failure
-
Gastrointestinal Cancer Symposium Orlando, FL: USA, 25-25 January Abstract 9
-
Ku, G.Y., Bains, M., Rizk, N., Shah, M.A., Rusch, V., Capanu, M. et al. (2007) Phase II trial of pre-operative cisplatin/irinotecan and radiotherapy for locally advanced esophageal cancer: Pet scan after induction therapy may identify early treatment failure. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 25-25 January 2007: Abstract 9.
-
(2007)
-
-
Ku, G.Y.1
Bains, M.2
Rizk, N.3
Shah, M.A.4
Rusch, V.5
Capanu, M.6
-
66
-
-
84993818754
-
Phase II trial of pre-operative cisplatin/irinotecan and radiotherapy for locally advanced esophageal cancer: pet scan after induction therapy may identify early treatment failure
-
Gastrointestinal Cancer Symposium Orlando, FL: USA, 25-25 January Abstract 9
-
Ku, G.Y., Bains, M., Rizk, N., Shah, M.A., Rusch, V., Capanu, M. et al. (2008) Phase II trial of pre-operative cisplatin/irinotecan and radiotherapy for locally advanced esophageal cancer: pet scan after induction therapy may identify early treatment failure. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 25-25 January 2007: Abstract 9.
-
(2008)
-
-
Ku, G.Y.1
Bains, M.2
Rizk, N.3
Shah, M.A.4
Rusch, V.5
Capanu, M.6
-
67
-
-
2642570227
-
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer
-
Kulke, M.H., Odze, R.D., Mueller, J.D., Wang, H., Redston, M. and Bertagnolli, M.M. ( 2004) Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg 127: 1579-1586.
-
(2004)
J Thorac Cardiovasc Surg
, vol.127
, pp. 1579-1586
-
-
Kulke, M.H.1
Odze, R.D.2
Mueller, J.D.3
Wang, H.4
Redston, M.5
Bertagnolli, M.M.6
-
68
-
-
33846220461
-
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas
-
Kwak, E.L., Jankowski, J., Thayer, S.P., Lauwers, G.Y., Brannigan, B.W., Harris, P.L. et al. (2006) Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12: 4283-4287.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 4283-4287
-
-
Kwak, E.L.1
Jankowski, J.2
Thayer, S.P.3
Lauwers, G.Y.4
Brannigan, B.W.5
Harris, P.L.6
-
69
-
-
1242293090
-
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLC
-
Langer, C.J. ( 2004) Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLC. Int J Radiat Oncol Biol Phys 58: 991-1002.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.58
, pp. 991-1002
-
-
Langer, C.J.1
-
70
-
-
3442899114
-
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma
-
Lee, J.L., Park, S.I., Kim, S.B., Jung, H.Y., Lee, G.H., Kim, J.H. et al. (2004) A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15: 947-954.
-
(2004)
Ann Oncol
, vol.15
, pp. 947-954
-
-
Lee, J.L.1
Park, S.I.2
Kim, S.B.3
Jung, H.Y.4
Lee, G.H.5
Kim, J.H.6
-
71
-
-
0242574321
-
BRAFand KRAS mutations in stomach cancer
-
Lee, S.H., Lee, J.W., Soung, Y.H., Kim, H.S., Park, W.S., Kim, S.Y. et al. (2003) BRAFand KRAS mutations in stomach cancer. Oncogene 22: 6942-6945.
-
(2003)
Oncogene
, vol.22
, pp. 6942-6945
-
-
Lee, S.H.1
Lee, J.W.2
Soung, Y.H.3
Kim, H.S.4
Park, W.S.5
Kim, S.Y.6
-
72
-
-
84993802094
-
Oxaliplatin (Oxp) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to durgery (S) for potentially curable esophageal adenocarcinoma (Ea): A Southwest Oncology Group (SWOG) Phase II trial with molecular correlates (S0356)
-
Amercan Society of Clinical Oncology, Annual Proceedings Orlando, FL: Abstract #4513
-
Leichman, L., Goldman, B.H., Benedetti, J.K., Billingsley, K.G., Thomas, C.R., Iqbal, S. et al. (2009) Oxaliplatin (Oxp) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to durgery (S) for potentially curable esophageal adenocarcinoma (Ea): A Southwest Oncology Group (SWOG) Phase II trial with molecular correlates (S0356). Amercan Society of Clinical Oncology, Annual Proceedings, Orlando, FL: Abstract #4513.
-
(2009)
-
-
Leichman, L.1
Goldman, B.H.2
Benedetti, J.K.3
Billingsley, K.G.4
Thomas, C.R.5
Iqbal, S.6
-
73
-
-
38649099966
-
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
-
Lievre, A., Bachet, J.B., Boige, V., Cayre, A., Le Corre, D., Buc, E. et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379.
-
(2008)
J Clin Oncol
, vol.26
, pp. 374-379
-
-
Lievre, A.1
Bachet, J.B.2
Boige, V.3
Cayre, A.4
Le Corre, D.5
Buc, E.6
-
74
-
-
34548185461
-
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The municon phase II trial
-
Lordick, F., Ott, K., Krause, B.J., Weber, W.A., Becker, K., Stein, H.J. et al. (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The municon phase II trial. Lancet Oncol 8: 797-805.
-
(2007)
Lancet Oncol
, vol.8
, pp. 797-805
-
-
Lordick, F.1
Ott, K.2
Krause, B.J.3
Weber, W.A.4
Becker, K.5
Stein, H.J.6
-
75
-
-
53049091239
-
Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: Results of a phase I/II Trial
-
Lorenzen, S., Brucher, B., Zimmermann, F., Geinitz, H., Riera, J., Schuster, T. et al. (2008) Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: Results of a phase I/II Trial. Br J Cancer 99: 1020-1026.
-
(2008)
Br J Cancer
, vol.99
, pp. 1020-1026
-
-
Lorenzen, S.1
Brucher, B.2
Zimmermann, F.3
Geinitz, H.4
Riera, J.5
Schuster, T.6
-
76
-
-
38149024196
-
Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer
-
Lurje, G., Zhang, W., Yang, D., Groshen, S., Hendifar, A.E., Husain, H. et al. (2008) Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics 18: 161-168.
-
(2008)
Pharmacogenet Genomics
, vol.18
, pp. 161-168
-
-
Lurje, G.1
Zhang, W.2
Yang, D.3
Groshen, S.4
Hendifar, A.E.5
Husain, H.6
-
77
-
-
33847343360
-
Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers
-
Luthra, M.G., Ajani, J.A., Izzo, J., Ensor, J., Wu, T.T., Rashid, A. et al. (2007) Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res 13: 912-919.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 912-919
-
-
Luthra, M.G.1
Ajani, J.A.2
Izzo, J.3
Ensor, J.4
Wu, T.T.5
Rashid, A.6
-
78
-
-
33644823793
-
Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation
-
Luthra, R., Wu, T.T., Luthra, M.G., Izzo, J., Lopez-Alvarez, E., Zhang, L. et al. (2006) Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 24: 259-267.
-
(2006)
J Clin Oncol
, vol.24
, pp. 259-267
-
-
Luthra, R.1
Wu, T.T.2
Luthra, M.G.3
Izzo, J.4
Lopez-Alvarez, E.5
Zhang, L.6
-
79
-
-
84993788772
-
Neoadjuvant therapy of gastric cancer with irinotecan, cisplatin, and cetuximab followed by surgical resection and adjuvant chemoradiation
-
Gastrointestinal Cancer Symposium Orlando, FL: USA, 15-17 January Abstract 58
-
Ma, H.Y., Ryan, T., Newman, E., Cohen, D.J., Choi, H. and Hochster, H.S. ( 2009) Neoadjuvant therapy of gastric cancer with irinotecan, cisplatin, and cetuximab followed by surgical resection and adjuvant chemoradiation. Gastrointestinal Cancer Symposium, Orlando, FL, USA, 15-17 January 2009: Abstract 58.
-
(2009)
-
-
Ma, H.Y.1
Ryan, T.2
Newman, E.3
Cohen, D.J.4
Choi, H.5
Hochster, H.S.6
-
80
-
-
34047179551
-
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer
-
Machiels, J.P., Sempoux, C., Scalliet, P., Coche, J.C., Humblet, Y., van Cutsem, E. et al. (2007) Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 18: 738-744.
-
(2007)
Ann Oncol
, vol.18
, pp. 738-744
-
-
Machiels, J.P.1
Sempoux, C.2
Scalliet, P.3
Coche, J.C.4
Humblet, Y.5
van Cutsem, E.6
-
81
-
-
0030066037
-
Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
-
Maeda, K., Chung, Y.S., Ogawa, Y., Takatsuka, S., Kang, S.M., Ogawa, M. et al. (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858-863.
-
(1996)
Cancer
, vol.77
, pp. 858-863
-
-
Maeda, K.1
Chung, Y.S.2
Ogawa, Y.3
Takatsuka, S.4
Kang, S.M.5
Ogawa, M.6
-
82
-
-
39449115649
-
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer
-
Matsubara, J., Nishina, T., Yamada, Y., Moriwaki, T., Shimoda, T., Kajiwara, T. et al. (2008) Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 98: 832-839.
-
(2008)
Br J Cancer
, vol.98
, pp. 832-839
-
-
Matsubara, J.1
Nishina, T.2
Yamada, Y.3
Moriwaki, T.4
Shimoda, T.5
Kajiwara, T.6
-
83
-
-
0242637476
-
Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer
-
McDonnell, C.O., Bouchier-Hayes, D.J., Toomey, D., Foley, D., Kay, E.W., Leen, E. et al. (2003) Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer. Br J Surg 90: 1373-1378.
-
(2003)
Br J Surg
, vol.90
, pp. 1373-1378
-
-
McDonnell, C.O.1
Bouchier-Hayes, D.J.2
Toomey, D.3
Foley, D.4
Kay, E.W.5
Leen, E.6
-
84
-
-
27244450053
-
Trastuzumab-mediated antibody-dependent cellular cytotoxicity against Esophageal squamous cell carcinoma
-
Mimura, K., Kono, K., Hanawa, M., Kanzaki, M., Nakao, A., Ooi, A. et al. (2005) Trastuzumab-mediated antibody-dependent cellular cytotoxicity against Esophageal squamous cell carcinoma. Clin Cancer Res 11: 4898-4904.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4898-4904
-
-
Mimura, K.1
Kono, K.2
Hanawa, M.3
Kanzaki, M.4
Nakao, A.5
Ooi, A.6
-
85
-
-
0036499029
-
Int 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy
-
Minsky, B.D., Pajak, T.F., Ginsberg, R.J., Pisansky, T.M., Martenson, J., Komaki, R. et al. (2002) Int 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 20: 1167-1174.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1167-1174
-
-
Minsky, B.D.1
Pajak, T.F.2
Ginsberg, R.J.3
Pisansky, T.M.4
Martenson, J.5
Komaki, R.6
-
86
-
-
0026340050
-
Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer
-
Mukaida, H., Toi, M., Hirai, T., Yamashita, Y. and Toge, T. ( 1991) Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 68: 142-148.
-
(1991)
Cancer
, vol.68
, pp. 142-148
-
-
Mukaida, H.1
Toi, M.2
Hirai, T.3
Yamashita, Y.4
Toge, T.5
-
87
-
-
84993733564
-
Multicenter phase II study of Rad 001 for previously treated metastatic gastric cancer (MGC): Preliminary results
-
American Society of Clinial Oncology, Annual Proceedings Chicago, IL: USA: Abstract 4541
-
Muro, K., Boku, N., Yamada, Y., Nishina, T., Doi, T., Takiuchi, H. et al. (2008) Multicenter phase II study of Rad 001 for previously treated metastatic gastric cancer (MGC): Preliminary results. American Society of Clinial Oncology, Annual Proceedings, Chicago, IL, USA: Abstract 4541.
-
(2008)
-
-
Muro, K.1
Boku, N.2
Yamada, Y.3
Nishina, T.4
Doi, T.5
Takiuchi, H.6
-
88
-
-
34347270571
-
Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma
-
O’Cconnor, B.M., Chadha, M.K., Pande, A., Lombardo, J.C., Nwogu, C.E., Nava, H.R. et al. (2007) Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J 13: 119-124.
-
(2007)
Cancer J
, vol.13
, pp. 119-124
-
-
O’Cconnor, B.M.1
Chadha, M.K.2
Pande, A.3
Lombardo, J.C.4
Nwogu, C.E.5
Nava, H.R.6
-
89
-
-
84993782280
-
Recent results of phase II study of Ps-341 (bortezomib) with or without irinotecan in patients (Pts) with advanced gastric adenocarcinomas (AGA)
-
Gastrointestinal Cancer Symposium Orlando, FL: USA, 15-17 January Abstract:45
-
Ocean, A.J., Schnoll-Sussman, F., Chen, X.E., Keresztes, R., Holloway, S., Matthews, N. et al. (2007) Recent results of phase II study of Ps-341 (bortezomib) with or without irinotecan in patients (Pts) with advanced gastric adenocarcinomas (AGA). Gastrointestinal Cancer Symposium, Orlando, FL, USA, 15-17 January 2007. Abstract:45.
-
(2007)
-
-
Ocean, A.J.1
Schnoll-Sussman, F.2
Chen, X.E.3
Keresztes, R.4
Holloway, S.5
Matthews, N.6
-
90
-
-
33748435058
-
DNA repair by ERCC 1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
-
Olaussen, K.A., Dunant, A., Fouret, P., Brambilla, E., Andre, F., Haddad, V. et al. (2006) DNA repair by ERCC 1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991.
-
(2006)
N Engl J Med
, vol.355
, pp. 983-991
-
-
Olaussen, K.A.1
Dunant, A.2
Fouret, P.3
Brambilla, E.4
Andre, F.5
Haddad, V.6
-
91
-
-
0036006453
-
Prostaglandin E 2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy
-
Pai, R., Soreghan, B., Szabo, I.L., Pavelka, M., Baatar, D. and Tarnawski, A.S. ( 2002) Prostaglandin E 2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8: 289-293.
-
(2002)
Nat Med
, vol.8
, pp. 289-293
-
-
Pai, R.1
Soreghan, B.2
Szabo, I.L.3
Pavelka, M.4
Baatar, D.5
Tarnawski, A.S.6
-
92
-
-
14944385553
-
Global cancer statistics
-
Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. ( 2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
93
-
-
0034473393
-
Trastuzumab and chemotherapeutics: Drug interactions and synergies
-
Pegram, M.D., Lopez, A., Konecny, G. and Slamon, D.J. ( 2000) Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 27: 21-25.
-
(2000)
Semin Oncol
, vol.27
, pp. 21-25
-
-
Pegram, M.D.1
Lopez, A.2
Konecny, G.3
Slamon, D.J.4
-
94
-
-
0027526884
-
Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction
-
Pera, M., Cameron, A.J., Trastek, V.F., Carpenter, H.A. and Zinsmeister, A.R. ( 1993) Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104: 510-513.
-
(1993)
Gastroenterology
, vol.104
, pp. 510-513
-
-
Pera, M.1
Cameron, A.J.2
Trastek, V.F.3
Carpenter, H.A.4
Zinsmeister, A.R.5
-
95
-
-
34247255400
-
Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib: Does intratumoral heterogeneity matter
-
Personeni, N. ( 2006) Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib: Does intratumoral heterogeneity matter? J Clin Oncol 24: 5465.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5465
-
-
Personeni, N.1
-
96
-
-
33847663871
-
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (Folcetux Study)
-
Pinto, C., Di Fabio, F., Siena, S., Cascinu, S., Rojas Llimpe, F.L., Ceccarelli, C. et al. (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (Folcetux Study). Ann Oncol 18: 510-517.
-
(2007)
Ann Oncol
, vol.18
, pp. 510-517
-
-
Pinto, C.1
Di Fabio, F.2
Siena, S.3
Cascinu, S.4
Rojas Llimpe, F.L.5
Ceccarelli, C.6
-
97
-
-
2342557044
-
Targeted therapies for non-small-cell lung vancer: Biology, rationale, and preclinical results from a radiation oncology perspective
-
Raben, D., Helfrich, B. and Bunn Jr, P.A. ( 2004) Targeted therapies for non-small-cell lung vancer: Biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys 59: 27-38.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.59
, pp. 27-38
-
-
Raben, D.1
Helfrich, B.2
Bunn Jr, P.A.3
-
98
-
-
84993832087
-
EGFR-specific tyrosine kinase inhibitor, erlotinib, in combination with ionizing radiation for the treatment of esophageal carcinoma cells
-
Presented at: International Conference on Molecular targets and Cancer Therapeutics Boston
-
Raisch, K.P., Russo, S.M., Seay, L.L., and Al., E. ( 2003) EGFR-specific tyrosine kinase inhibitor, erlotinib, in combination with ionizing radiation for the treatment of esophageal carcinoma cells. Presented at: International Conference on Molecular targets and Cancer Therapeutics Boston.
-
(2003)
-
-
Raisch, K.P.1
Russo, S.M.2
Seay, L.L.3
Al, E.4
-
99
-
-
34247639018
-
Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer
-
Reynolds, J.V., Muldoon, C., Hollywood, D., Ravi, N., Rowley, S., O’Byrne, K. et al. (2007) Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 245: 707-716.
-
(2007)
Ann Surg
, vol.245
, pp. 707-716
-
-
Reynolds, J.V.1
Muldoon, C.2
Hollywood, D.3
Ravi, N.4
Rowley, S.5
O’Byrne, K.6
-
100
-
-
32944481596
-
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor Exon 19 and Exon 21 mutations treated with gefitinib or Erlotinib
-
Riely, G.J., Pao, W., Pham, D., Li, A.R., Rizvi, N., Venkatraman, E.S. et al. (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor Exon 19 and Exon 21 mutations treated with gefitinib or Erlotinib. Clin Cancer Res 12: 839-844.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 839-844
-
-
Riely, G.J.1
Pao, W.2
Pham, D.3
Li, A.R.4
Rizvi, N.5
Venkatraman, E.S.6
-
101
-
-
39749153032
-
Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer
-
Rodel, C., Arnold, D., Hipp, M., Liersch, T., Dellas, K., Iesalnieks, I. et al. (2008) Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 70: 1081-1086.
-
(2008)
Int J Radiat Oncol Biol Phys
, vol.70
, pp. 1081-1086
-
-
Rodel, C.1
Arnold, D.2
Hipp, M.3
Liersch, T.4
Dellas, K.5
Iesalnieks, I.6
-
102
-
-
33745223867
-
Concurrent cisplatin, 5-Fu, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer
-
Roof, K.S., Coen, J., Lynch, T.J., Wright, C., Fidias, P., Willett, C.G. et al. (2006) Concurrent cisplatin, 5-Fu, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 65: 1120-1128.
-
(2006)
Int J Radiat Oncol Biol Phys
, vol.65
, pp. 1120-1128
-
-
Roof, K.S.1
Coen, J.2
Lynch, T.J.3
Wright, C.4
Fidias, P.5
Willett, C.G.6
-
103
-
-
84993802426
-
(2009) Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (Sakk 75/02)
-
Ruhstaller, T., Widmer, L., Schuller, J.C., Roth, A., Hess, V., Mingrone, W. et al. (2009) Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (Sakk 75/02). Ann Oncol 22: 22.
-
Ann Oncol
, vol.22
, pp. 22
-
-
Ruhstaller, T.1
Widmer, L.2
Schuller, J.C.3
Roth, A.4
Hess, V.5
Mingrone, W.6
-
104
-
-
33846227021
-
Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER 2 overexpressing, esophageal adenocarcinoma
-
Safran, H., Dipetrillo, T., Akerman, P., Ng, T., Evans, D., Steinhoff, M. et al. (2007) Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER 2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 67: 405-409.
-
(2007)
Int J Radiat Oncol Biol Phys
, vol.67
, pp. 405-409
-
-
Safran, H.1
Dipetrillo, T.2
Akerman, P.3
Ng, T.4
Evans, D.5
Steinhoff, M.6
-
105
-
-
0035078336
-
Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer
-
Safran, H., Gaissert, H., Akerman, P., Hesketh, P.J., Chen, M.H., Moore, T. et al. (2001) Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 19: 1-7.
-
(2001)
Cancer Invest
, vol.19
, pp. 1-7
-
-
Safran, H.1
Gaissert, H.2
Akerman, P.3
Hesketh, P.J.4
Chen, M.H.5
Moore, T.6
-
106
-
-
38149088836
-
Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity
-
Safran, H., Suntharalingam, M., Dipetrillo, T., Ng, T., Doyle, L.A., Krasna, M. et al. (2008) Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity. Int J Radiat Oncol Biol Phys 70: 391-395.
-
(2008)
Int J Radiat Oncol Biol Phys
, vol.70
, pp. 391-395
-
-
Safran, H.1
Suntharalingam, M.2
Dipetrillo, T.3
Ng, T.4
Doyle, L.A.5
Krasna, M.6
-
107
-
-
11144352181
-
Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/ neu oncoprotein
-
Sato, S., Kajiyama, Y., Sugano, M., Iwanuma, Y., Sonoue, H., Matsumoto, T. et al. (2005) Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/ neu oncoprotein. Int J Radiat Oncol Biol Phys 61: 203-211.
-
(2005)
Int J Radiat Oncol Biol Phys
, vol.61
, pp. 203-211
-
-
Sato, S.1
Kajiyama, Y.2
Sugano, M.3
Iwanuma, Y.4
Sonoue, H.5
Matsumoto, T.6
-
108
-
-
84930816831
-
Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954
-
Amercan Society of Clinical Oncology, Annual Proceedings Orlando, FL: Abstract #4510
-
Schuhmacher, C., Schlag, P., Lordick, F., Hohenberger, W., Heise, J., Haag, C. et al. (2009) Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. Amercan Society of Clinical Oncology, Annual Proceedings, Orlando, FL: Abstract #4510.
-
(2009)
-
-
Schuhmacher, C.1
Schlag, P.2
Lordick, F.3
Hohenberger, W.4
Heise, J.5
Haag, C.6
-
109
-
-
84993793742
-
-
American Society of Clinical Oncology Chicago, IL: USA, 30 May-3 June Abstract
-
Schuller, J.C., Balmer-Majno, S., Mingrone, W., Hess, V., Von Moos, R., Borner, M. et al. (2008) Preoperative induction chemotherapy with docetaxel-cisplatin followed by concurrent docetaxel-cisplatin and radiation therapy (Rt) in patients with locally advanced esophageal cancer: Final results of the multicenter phase Ll trial sakk 75/02. American Society of Clinical Oncology, Chicago, IL, USA, 30 May-3 June 2008: Abstract 4550.
-
(2008)
Preoperative induction chemotherapy with docetaxel-cisplatin followed by concurrent docetaxel-cisplatin and radiation therapy (Rt) in patients with locally advanced esophageal cancer: Final results of the multicenter phase Ll trial sakk 75/02
, pp. 4550
-
-
Schuller, J.C.1
Balmer-Majno, S.2
Mingrone, W.3
Hess, V.4
Von Moos, R.5
Borner, M.6
-
110
-
-
84993733520
-
Preoperative cetuximab and radiation (Xrt) for patients (Pts) with surgically resectable esophageal and gastroesophageal (Ge) junction carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas-Southwestern
-
American Society of Clinical Oncology Chicago, IL: USA, 1-5 June Abstract 4564
-
Sgroi, M.M., Hanna, N.H., Mccollum, A.D., Bechar, N., Dimaio, M., Hammoud, Z. et al. (2008) Preoperative cetuximab and radiation (Xrt) for patients (Pts) with surgically resectable esophageal and gastroesophageal (Ge) junction carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas-Southwestern. American Society of Clinical Oncology, Chicago, IL, USA, 1-5 June 2008: Abstract 4564.
-
(2008)
-
-
Sgroi, M.M.1
Hanna, N.H.2
Mccollum, A.D.3
Bechar, N.4
Dimaio, M.5
Hammoud, Z.6
-
111
-
-
33846629672
-
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma
-
Shah, M.A., Ramanathan, R.K., Ilson, D.H., Levnor, A., D’adamo, D., O’Reilly, E. et al. (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24: 5201-5206.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5201-5206
-
-
Shah, M.A.1
Ramanathan, R.K.2
Ilson, D.H.3
Levnor, A.4
D’adamo, D.5
O’Reilly, E.6
-
112
-
-
33744529601
-
Phase I/II adenoviral P 53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma
-
Shimada, H., Matsubara, H., Shiratori, T., Shimizu, T., Miyazaki, S., Okazumi, S. et al. (2006) Phase I/II adenoviral P 53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 97: 554-561.
-
(2006)
Cancer Sci
, vol.97
, pp. 554-561
-
-
Shimada, H.1
Matsubara, H.2
Shiratori, T.3
Shimizu, T.4
Miyazaki, S.5
Okazumi, S.6
-
113
-
-
0031865433
-
Expression of epidermal growth factor receptor family proteins (EGFR, C-ERBB-2 and C-ERBB-3) in gastric cancer and chronic gastritis
-
Slesak, B., Harlozinska, A., Porebska, I., Bojarowski, T., Lapinska, J., Rzeszutko, M. et al. (1998) Expression of epidermal growth factor receptor family proteins (EGFR, C-ERBB-2 and C-ERBB-3) in gastric cancer and chronic gastritis. Anticancer Res 18: 2727-2732.
-
(1998)
Anticancer Res
, vol.18
, pp. 2727-2732
-
-
Slesak, B.1
Harlozinska, A.2
Porebska, I.3
Bojarowski, T.4
Lapinska, J.5
Rzeszutko, M.6
-
114
-
-
20244387586
-
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus
-
Stahl, M., Stuschke, M., Lehmann, N., Meyer, H.J., Walz, M.K., Seeber, S. et al. (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23: 2310-2317.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2310-2317
-
-
Stahl, M.1
Stuschke, M.2
Lehmann, N.3
Meyer, H.J.4
Walz, M.K.5
Seeber, S.6
-
115
-
-
60849118127
-
(2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction
-
Stahl, M., Walz, M.K., Stuschke, M., Lehmann, N., Meyer, H.J., Riera-Knorrenschild, J. et al. (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27: 851-856.
-
J Clin Oncol
, vol.27
, pp. 851-856
-
-
Stahl, M.1
Walz, M.K.2
Stuschke, M.3
Lehmann, N.4
Meyer, H.J.5
Riera-Knorrenschild, J.6
-
116
-
-
70249098769
-
Long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus
-
American Society of Clinial Oncology, Annual Proceedings Chicago, IL: USA: Abstract 4530
-
Stahl, M., Wilke, H., Lehmann, N., Stuschke, M. and Group, G.O.C.S. ( 2008) Long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus. American Society of Clinial Oncology, Annual Proceedings, Chicago, IL, USA: Abstract 4530.
-
(2008)
-
-
Stahl, M.1
Wilke, H.2
Lehmann, N.3
Stuschke, M.4
Group, G.O.C.S.5
-
117
-
-
77953451873
-
-
American Society of Clinical Oncology Chicago, IL: USA: 1-5 June Abstract
-
Sun, W., Powell, M.E., O’Dwyer, P., Ansari, R.H. and Benson, A.B. ( 2008) A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). American Society of Clinical Oncology, Chicago, IL : USA: 1-5 June 2008: Abstract 4535.
-
(2008)
A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203)
, pp. 4535
-
-
Sun, W.1
Powell, M.E.2
O’Dwyer, P.3
Ansari, R.H.4
Benson, A.B.5
-
118
-
-
41949119177
-
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781
-
Tepper, J., Krasna, M.J., Niedzwiecki, D., Hollis, D., Reed, C.E., Goldberg, R. et al. (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26: 1086-1092.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1086-1092
-
-
Tepper, J.1
Krasna, M.J.2
Niedzwiecki, D.3
Hollis, D.4
Reed, C.E.5
Goldberg, R.6
-
119
-
-
16844368546
-
Phase II trial of erlotonib for second-line treatment in advanced esophageal cancer
-
American Society of Clinical Oncology, Gastrointestinal Cancer Symposium Abstract 5
-
Tew, W.P., Shah, M.A., Schwartz, G., Kelsen, D.P. and Ilson, D.H. ( 2005) Phase II trial of erlotonib for second-line treatment in advanced esophageal cancer. American Society of Clinical Oncology, Gastrointestinal Cancer Symposium: Abstract 5.
-
(2005)
-
-
Tew, W.P.1
Shah, M.A.2
Schwartz, G.3
Kelsen, D.P.4
Ilson, D.H.5
-
120
-
-
78651427477
-
-
American Society of Clinical Oncology Chicago, IL: USA, 1-5 June Abstract
-
Thirion, P.G., Michiels, S., Le Maître, A., Tierney, J. and Group, O.B.O.T.M.O.C.I.E.C.C. ( 2007) Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. American Society of Clinical Oncology, Chicago, IL, USA, 1-5 June 2007: Abstract 4512.
-
(2007)
Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma
, pp. 4512
-
-
Thirion, P.G.1
Michiels, S.2
Le Maître, A.3
Tierney, J.4
Group, O.B.O.T.M.O.C.I.E.C.C.5
-
121
-
-
28244455228
-
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma
-
Tuynman, J.B., Buskens, C.J., Kemper, K., Ten Kate, F.J., Offerhaus, G.J., Richel, D.J. et al. (2005) Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg 242: 840-849.
-
(2005)
Ann Surg
, vol.242
, pp. 840-849
-
-
Tuynman, J.B.1
Buskens, C.J.2
Kemper, K.3
Ten Kate, F.J.4
Offerhaus, G.J.5
Richel, D.J.6
-
122
-
-
40849119954
-
MET expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma
-
Tuynman, J.B., Lagarde, S.M., Ten Kate, F.J., Richel, D.J. and van Lanschot, J.J. ( 2008) MET expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 98: 1102-1108.
-
(2008)
Br J Cancer
, vol.98
, pp. 1102-1108
-
-
Tuynman, J.B.1
Lagarde, S.M.2
Ten Kate, F.J.3
Richel, D.J.4
van Lanschot, J.J.5
-
123
-
-
0035863382
-
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma
-
Urba, S.G., Orringer, M.B., Turrisi, A., Iannettoni, M., Forastiere, A. and Strawderman, M. ( 2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-313.
-
(2001)
J Clin Oncol
, vol.19
, pp. 305-313
-
-
Urba, S.G.1
Orringer, M.B.2
Turrisi, A.3
Iannettoni, M.4
Forastiere, A.5
Strawderman, M.6
-
124
-
-
70350204423
-
Efficacy results from the Toga trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
-
American Society of Clinial Oncology, Annual Proceedings Orlando, FL: USA, May 29-June 2: Abstract #LBA 4509
-
van Cutsem, E., Kang, K., Chung, H., Shen, L., Sawaki, A., Lordick, F. et al. (2009) Efficacy results from the Toga trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). American Society of Clinial Oncology, Annual Proceedings, Orlando, FL, USA, May 29-June 2: Abstract #LBA 4509.
-
(2009)
-
-
van Cutsem, E.1
Kang, K.2
Chung, H.3
Shen, L.4
Sawaki, A.5
Lordick, F.6
-
125
-
-
63849088630
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
-
van Cutsem, E., Kohne, C.H., Hitre, E., Zaluski, J., Chang Chien, C.R., Makhson, A. et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417.
-
(2009)
N Engl J Med
, vol.360
, pp. 1408-1417
-
-
van Cutsem, E.1
Kohne, C.H.2
Hitre, E.3
Zaluski, J.4
Chang Chien, C.R.5
Makhson, A.6
-
126
-
-
33750949065
-
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V 325 study group
-
van Cutsem, E., Moiseyenko, V.M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C. et al. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V 325 study group. J Clin Oncol 24: 4991-4997.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4991-4997
-
-
van Cutsem, E.1
Moiseyenko, V.M.2
Tjulandin, S.3
Majlis, A.4
Constenla, M.5
Boni, C.6
-
127
-
-
38349183886
-
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-Gastrointestinal Cancer Group
-
van Cutsem, E., van de Velde, C., Roth, A., Lordick, F., Kohne, C.H., Cascinu, S. et al. (2008) Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-Gastrointestinal Cancer Group. Eur J Cancer 44: 182-194.
-
(2008)
Eur J Cancer
, vol.44
, pp. 182-194
-
-
van Cutsem, E.1
van de Velde, C.2
Roth, A.3
Lordick, F.4
Kohne, C.H.5
Cascinu, S.6
-
128
-
-
0029737381
-
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma
-
Walsh, T.N., Noonan, N., Hollywood, D., Kelly, A., Keeling, N. and Hennessy, T.P. ( 1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335: 462-467.
-
(1996)
N Engl J Med
, vol.335
, pp. 462-467
-
-
Walsh, T.N.1
Noonan, N.2
Hollywood, D.3
Kelly, A.4
Keeling, N.5
Hennessy, T.P.6
-
129
-
-
28544439939
-
High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer
-
Xi, H., Baldus, S.E., Warnecke-Eberz, U., Brabender, J., Neiss, S., Metzger, R. et al. (2005) High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 11: 8341-8347.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 8341-8347
-
-
Xi, H.1
Baldus, S.E.2
Warnecke-Eberz, U.3
Brabender, J.4
Neiss, S.5
Metzger, R.6
-
130
-
-
0035150992
-
The clinical significance of MMP-1 expression in oesophageal carcinoma
-
Yamashita, K., Mori, M., Kataoka, A., Inoue, H. and Sugimachi, K. ( 2001) The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer 84: 276-282.
-
(2001)
Br J Cancer
, vol.84
, pp. 276-282
-
-
Yamashita, K.1
Mori, M.2
Kataoka, A.3
Inoue, H.4
Sugimachi, K.5
|